Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Efficiency of chemotherapy is often limited by low therapeutic index of the drug as well as emergence of inherent and acquired drug resistance in cancer cells. As a common strategy to overcome drug resistance, higher doses of chemo-agents are administered. However, adverse side effects are usually increased as a consequence. A potentially effective approach is to combine chemotherapy with other therapeutic strategies such as small interfering RNAs (siRNAs) that allow the use of lower yet efficient doses of the anticancer drugs. We previously developed epidermal growth factor receptor (EGFR)-targeted chitosan (CS) nanoparticles as a versatile delivery system for silencing the essential mitotic checkpoint gene Mad2, and induce cell death. Here, we tested this system as a single therapy and in combination with cisplatin in cisplatin sensitive and resistant lung cancer models, and characterized its in vivo efficacy and safety. Combination treatment resulted in significant improvement in tumor inhibition that was strikingly more effective in cisplatin-resistant tumors. Importantly, effective cisplatin dosage was dramatically reduced in the co-therapy regimen resulting in negligible toxic effects from the drug as confirmed by parameters such as body weight gain, biochemical markers of hepatic and renal function, and histopathology of liver/kidney/spleen tissues. Overall, we demonstrate that the combination of Mad2 siRNA-loaded CS nanoparticles strategy with chemotherapeutic agents such as cisplatin constitutes an efficient and safe approach for the treatment of drug resistant tumors. STATEMENT OF SIGNIFICANCE: Lung cancer remains one of the leading killers in the United States and around the world. Platinum agents, including cisplatin, are the first line treatment in lung cancer, including non-small cell lung cancer (NSCLC), which is the predominant form of lung cancer. In this study, we have evaluated Mad2 cell-cycle checkpoint gene silencing using small interfering RNA (siRNA) delivered systemically using epidermal growth factor receptor-targeted chitosan nanoparticles in drug sensitive and resistant models of NSCLC. Our results show that Mad2 gene silencing using targeted chitosan nanoparticles has tremendous potential in overcoming platinum resistance in NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537 · cited 2×
“This leads to cessation of cell division and rapid cell death due to oxidative stress, 56 DNA damage and activation of the apoptotic machinery of the cell [5].”
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801 · cited 1×
“In case cells are not able to repair DNA damage, 62 two different modes of cell death are induced, necrosis and apoptosis [9].”
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Cell death by mitotic catastrophe: a molecular definition
Castedo, M., Perfettini, J.-L., Roumier, T., Andreau, K., Medema, R., & Kroemer, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207528 · Cited by 1,269 · cited 1×
“This process is designated by mitotic catastrophe and although a small minority of 99 daughter cells could survive, they are condemned to death due to the absence of genes coding 100 for essential proteins [25].”
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
Michel, L., Diaz-Rodriguez, E., Narayan, G., Hernando, E., Murty, V. V. V. S., & Benezra, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306069101 · Cited by 188 · cited 1×
“If cells are able to escape 364 G2/M arrest and progress to the mitotic phase, cell will fail to arrest and an aberrant 365 chromosome segregation will take place in the absence of Mad2, triggering cell death [16, 22].”
Cited by
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Current Advances in Chitosan Nanoparticles Based Drug Delivery and Targeting
Garg, U., Chauhan, S., Nagaich, U., & Jain, N. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.023 · Cited by 505
Chitosan-Based Nanomaterials for Drug Delivery
Li, J., Cai, C., Li, J., Li, J., Li, J., Sun, T., Wang, L., Wu, H., & Yu, G. (2018) · Molecules · doi:10.3390/molecules23102661 · Cited by 481
Chitosan Nanoparticles at the Biological Interface: Implications for Drug Delivery
Aibani, N., Rai, R., Patel, P., Cuddihy, G., & Wasan, E. K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101686 · Cited by 419
Mehta, M., Deeksha, Tewari, D., Gupta, G., Awasthi, R., Singh, H., Pandey, P., Chellappan, D. K., Wadhwa, R., Collet, T., et al. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.05.028 · Cited by 397
Metadata
- Authors
- Nascimento, A. V., Singh, A., Bousbaa, H., Ferreira, D., Sarmento, B., & Amiji, M. M.
- Venue
- Acta Biomaterialia
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 47
- Pages
- 71-80
- ISSN
- 1742-7061 (ISSN-L)
- OpenAlex
- W2529674712
- Cited by
- 124
- References
- 6
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.